LY01005与诺雷得®治疗绝经前乳腺癌患者的Ⅲ期多中心随机对照研究
该前瞻性Ⅲ期多中心随机对照研究纳入188例中国绝经前乳腺癌患者,1∶1随机接受LY01005或诺雷得®每28天1次共3次,同时口服他莫昔芬。主要终点为第29至85天维持E2≤30 pg/ml的累积概率,LY01005组93.1% vs 诺雷得®组86.3%,率差6.8%(95%CI:-2.3%~15.9%),达到非劣效标准;两组安全性特征相似。
要点
- LY01005组第29至85天维持E2≤30 pg/ml的累积概率为93.1%,诺雷得®组为86.3%。
- 两组累积概率率差为6.8%(95%CI:-2.3%~15.9%),达到非劣效标准。
- 两组E2、LH、FSH较基线变化相当,安全性特征相似,整体耐受性良好。
核心结论
- LY01005每28天1次治疗绝经前乳腺癌患者,可持续有效维持血清E2至绝经后水平,临床疗效与诺雷得®相当,安全性特征相似,整体耐受性良好。
研究设计与样本
- 前瞻性、多中心、随机对照Ⅲ期研究,2020年10月至2021年11月在34家医院入组188例绝经前乳腺癌患者,1∶1随机接受LY01005或诺雷得®每28天1次连续3次,所有患者同时口服他莫昔芬。
- 共有188例患者随机入组,187例患者接受LY01005或诺雷得®治疗,其中LY01005组93例,诺雷得®组94例。
主要发现
- LY01005组第29天至第85天维持E2≤30 pg/ml的累积概率为93.1%,诺雷得®组为86.3%,两组率差为6.8%(95%CI:-2.3%~15.9%)。
- 两组血清E2、LH、FSH第29天给药前至第85天与基线相比变化相当(E2:LY01005组89.34%~90.23% vs 诺雷得®组82.11%~85.02%;LH:LY01005组88.89%~95.52% vs 诺雷得®组89.70%~97.02%;FSH:LY01005组75.36%~80.85% vs 诺雷得®组73.07%~80.24%)。
- LY01005组连续3次给药后,血清LH和FSH均在首次给药后一过性升高,第2天达峰后下降,第29天达到较低浓度水平并维持至第85天。
- 两组安全性特征相似。
关键数值与推荐
- 主要疗效终点为非劣效设计,主要疗效指标率差的95%CI下限不低于-10%即达到非劣效标准,本研究率差6.8%(95%CI:-2.3%~15.9%)满足该标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: To compare the efficacy and safety of monthly administrations of gonadotropin releasing hormone (GnRH) agonists LY01005 and Zoladex® in Chinese patients with premenopausal breast cancer. Methods: From October 2020 to November 2021, 188 premenopausal breast cancer patients were enrolled in 34 hospitals and randomized 1:1 to receive either LY01005 or Zoladex® every 28 days for a total of three injections. All patients concomitantly received oral tamoxifen (TAM). The primary efficacy endpoint was cumulative probability of maintaining menopausal level [oestradiol (E2) ≤30 pg/ml] from day 29 to day 85. The second efficacy endpoint included changes in E2, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) compared with the baseline. Pharmacokinetics (PK), pharmacodynamics (PD), and safety were analyzed. The study also evaluated the pharmacokinetic and pharmacodynamic characteristics of LY01005. Results: A total of 188 patients were randomised and 187 patients received either LY01005 or Zoladex®. Cumulative probabilities of maintaining menopausal level (E2≤30 pg/ml) from day 29 to day 85 were 93.1% for LY01005 and 86.3% for Zoladex®. The between-group difference was 6.8% (95% CI: -2.3%, 15.9%) and primary efficacy in the LY01005 group was not inferior to that in the Zoladex® group. Changes in E2, LH, and FSH levels compared with the baseline were equivalent between the two groups (E2: 89.34% to 90.23% vs. 82.11% to 85.02%; LH: 88.89% to 95.52% vs. 89.70% to 97.02%; FSH: 75.36% to 80.85% vs.73.07% to 80.24%, respectively). After three consecutive doses of LY01005, the LH and FSH levels of the subjects showed a transient increase after the first dose, reached a peak on the second day and then started to decrease. The LH and FSH reached a lower level and remained at or below that level until the 85th day. Both treatments were well-tolerated. Conclusion: LY01005 is as effective as Zoladex® in suppressing E2 to menopausal levels in Chinese patients with premenopausal breast cancer, with a similar safety profile. 目的: 探讨促性腺激素释放激素激动剂LY01005和诺雷得®在中国绝经前乳腺癌患者中的疗效和安全性。 方法: 研究为前瞻性研究,2020年10月至2021年11月期间在34家医院入组188例绝经前乳腺癌患者,以1∶1的比例随机接受LY01005或诺雷得®治疗,每28 d 1次,连续给药3次,所有患者同时口服他莫昔芬治疗。研究的主要疗效终点为给药第29天至第85天血清雌二醇(E2)维持在绝经后水平(≤30 pg/ml)的患者比例。次要终点包括血清E2、促黄体生成素(LH)和促卵泡生成素(FSH)较基线的变化及安全性特征。研究也评价LY01005的药代动力学、药效学特征。 结果: 共有188例乳腺癌患者随机入组,187例患者接受LY01005或诺雷得®治疗。LY01005组(n=93)和诺雷得®组(n=94)给药第29天至第85天维持在绝经后水平(E2≤30 pg/ml)的患者比例分别为93.1%及86.3%,两组累积概率的率差为6.8%(95% CI:-2.3%~15.9%),满足主要疗效指标率差的95% CI下限不低于-10%,达到非劣效标准。两组第29天给药前至第85天血清E2、LH、FSH与基线相比变化相当(E2:89.34%~90.23%和82.11%~85.02%;LH:88.89%~95.52% 和89.70%~97.02%、FSH:75.36%~80.85%和73.07%~80.24%)。LY01005组受试者连续3次给药后,血清LH和FSH均在首次给药后呈现一过性升高,在第2天达峰,随后开始下降,第29天血清LH和FSH浓度达到较低浓度水平,之后维持在该浓度水平及以下直至第85天。两组安全性特征相似。 结论: LY01005每28 d 1次治疗绝经前乳腺癌患者,可持续有效维持血清E2至绝经后水平,临床疗效与诺雷得®相当,安全性特征相似,整体耐受性良好。.
引用
- Shao XY, Zhang QY, Niu ZF, et al. [Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex® for patients with premenopausal breast cancer]. Zhonghua Zhong Liu Za Zhi. 2025. PMID: 40268551. doi:10.3760/cma.j.cn112152-20240126-00051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。